Catalysts / ABSI
Upcoming FDA decisions and readouts we track for Absci, each with the filing that announced it.
FreeBioList tracks 3 upcoming catalysts for Absci (ABSI, listed on Nasdaq). All of them concern ABS-201 (Androgenetic (pattern) hair loss; Endometriosis).
First on the list: the Phase 1/2 readout for ABS-201 (Androgenetic (pattern) hair loss), guided by the company to H2 2026. The furthest-out event tracked is H2 2027. By stage, the upcoming rows are 2 Phase 1/2 readouts and 1 Phase 2 readout.
All 3 rows link to SEC filings (8-K or 6-K). All have been verified by a person reading the filing itself, most recently on 12 Sep 2026. The methodology page explains each status.
Background reading: Clinical trial phases explained: Phase 1 to Phase 4.
| Company ▾ | Drug ▾ | Effect / indication | Next catalyst ▾ | Phase / type ▾ | Status ▾ | Source | Options |
|---|---|---|---|---|---|---|---|
| Absci ABSI · Nasdaq | ABS-201 | Androgenetic (pattern) hair loss | H2 2026 company guidance |
Phase 1/2 readout | Verified | 8-K exhibit 99.1 ↗ | Yes |
| Absci ABSI · Nasdaq | ABS-201 | Androgenetic (pattern) hair loss | Early 2027 company guidance |
Phase 1/2 readout | Verified | 8-K exhibit 99.1 ↗ | Yes |
| Absci ABSI · Nasdaq | ABS-201 | Endometriosis | H2 2027 company guidance |
Phase 2 readout | Verified | 8-K exhibit 99.1 ↗ | Yes |
FreeBioList